rHuEPO (recombinant human erythropoietin) is a haemopoietic growth factor and a primary regulator of erythropoiesis that is used for the treatment of chronic anaemia associated with RA (rheumatoid arthritis). Erythropoietin also appears to modulate a broad array of cellular processes, including progenitor stem-cell development, cellular integrity, angiogenesis and oxidative damage. These diverse activities suggest the exciting possibility of multiple roles for rHuEPO therapy in a variety of disorders other than RA, including cerebral ischaemia, myocardial infarction, chronic congestive heart failure and cancer. Thus it appears that rHuEPO may be a pleiotropic agent, capable of influencing tissue remodelling independently of its established erythropoietic role. Whereas these effects may be largely beneficial, dose-related side effects could have implications for the safe therapeutic use of rHuEPO and its illegal use as a performance-enhancing agent in endurance sports.
Conference Article| October 26 2005
Novel tissue remodelling roles for human recombinant erythropoietin
R. Grant 1
*Division of Science, Faculty of Creative Arts, Technology and Science, University of Luton, Park Square, Luton, Bedfordshire LU1 3JU, U.K.
1To whom correspondence should be addressed (email firstname.lastname@example.org)
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
P.J. Coussons, S. Baig, C. Fanutti, R. Grant; Novel tissue remodelling roles for human recombinant erythropoietin. Biochem Soc Trans 26 October 2005; 33 (5): 1129–1130. doi: https://doi.org/10.1042/BST0331129
Download citation file: